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Daneshgah-e-Bu Ali Sina, Hamedan, IranIntroduction: Monogenetic renal diseases, including recessively inherited nephrotic syndromes, represent
a signiﬁcant health burden despite being rare conditions. Precise diagnosis, including identiﬁcation of the
underlying molecular cause, is especially difﬁcult in low-income countries and/or if affected individuals are
unavailable for biochemical testing. Whole-exome sequencing (WES) has opened up novel diagnostic
perspectives for these settings. However, sometimes the DNA of affected individuals is not suitable for
WES due to low amounts or degradation.
Methods: We report on the use of parental WES with implementation of speciﬁc stepwise variant ﬁltering
to identify the underlying molecular cause of the childhood-onset nephrotic syndrome as nephrosialidosis
resulting from a mutation in NEU1.
Results: Sequencing both parents enabled a nephrosialidosis diagnosis in the deceased child. To date,
only 16 other cases of nephrosialidosis have been reported in the literature, with only 1 genetically
conﬁrmed case. After we reviewed the clinical information of all reported cases, we found that most pa-
tients presented with proteinuria, which started at between 2 and 3 years of age. Renal pathology showed
mainly focal segmental glomerulosclerosis (FSGS)with vacuolated cells, and steroid treatment was always
unsuccessful. Hepatomegaly was present in nearly all cases, whereas corneal clouding and a cherry red
spot on the macula was observed in only approximately 50% of cases. Fourteen of 16 previously reported
cases were no longer alive at the time of reporting.
Conclusions: Our ﬁndings demonstrate the power of parental WES to diagnose rare genetic diseases, such
as childhood-onset nephrotic syndrome. We further provide a comprehensive overview of the clinical
course of nephrosialidosis and raise awareness of this ultra-rare condition as an underlying cause of
FSGS.
Kidney Int Rep (2018) 3, 1454–1463; https://doi.org/10.1016/j.ekir.2018.07.015
KEYWORDS: nephrotic syndrome; NEU1; sialidosis; whole-exome sequencing
ª 2018 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).R are diseases are deﬁned as affecting <1 in 2000individuals of the population; however, together,
they represent a signiﬁcant disease burden. Extremespondence: Miriam Schmidts, Center for Pediatrics and
scent Medicine, University Hospital Freiburg, Freiburg Uni-
y, Faculty of Medicine, Freiburg, Germany. E-mail: miriam.
idts@uniklinik-freiburg.de
nd IS contributed equally to the paper.
ved 24 June 2018; revised 16 July 2018; accepted 23 July
published online 29 July 2018genotypic heterogeneity signiﬁcantly hampers the
diagnostic pathway, and in areas of the world with
limited medical and technical support, most families are
left without a deﬁnitive diagnosis. Death of the affected
individual with no possible further biochemical testing
causes additional diagnostic obstacles. Recent devel-
opment of next-generation sequencing (NGS) technolo-
gies, especially WES, has changed the rare disease
landscape dramatically, including the ﬁndings for renal
phenotypes, and more speciﬁcally, nephrotic syn-
dromes. Currently, WES also allows a molecularKidney International Reports (2018) 3, 1454–1463
R Marooﬁan et al.: Parental WES Diagnoses Sialidosis as Cause of NS TRANSLATIONAL RESEARCHdiagnosis for cases with limited clinical information or
laboratory workup, and is not signiﬁcantly inferior to
gene panels with regard to coverage1 while offering
much broader discovery possibilities for genes.
Nephrotic syndrome can occur as steroid-sensitive or
steroid resistant disease (SRNS); the latter is a frequent
cause of chronic kidney disease and renal failure, espe-
cially in the early decades of life. Histologically, FSGS is
commonly noted in SRNS. Exome sequencing and other
NGS technologies, such as gene panel sequencing, have
recently extended the number of genes found to be
causative to >30, and the genetic diagnosis rate has
likewise increased to approximately 30%.2
Sialidosis (Online Mendelian Inheritance in Man
[OMIN]# 256550) is a rare lysosomal storage disease
inherited in an autosomal-recessive fashion. It was ﬁrst
described clinically as a phenotype entity in 1968 by
Spranger and Wiedemann,3 and as lip-
omucopolysaccharidosis or mucolipidosis in 1970, and
neuraminidase deﬁciency in affected individuals was
detected in ﬁbroblasts as early as 1977. Biallelic loss of
function mutations in the gene encoding for neuramini-
dase, NEU1, was identiﬁed as a cause by Bonten et al.
nearly 20 years later.4,5 However, due to the paucity of the
phenotype and the diagnosis often being made clinically
and biochemically via testing of the enzyme activity (e.g.,
in patient ﬁbroblasts and urine analyses), only a few
molecularly conﬁrmed cases have been published to date.
NEU1 encodes for an enzyme, a-neuraminidase, which
forms a high molecular weight protein together with
cathepsin A; both enzymes together function as sialidase.
Therefore, dysfunction ofNeu1 results in accumulation of
sialylated glycoproteins/peptides and oligosaccharides in
lysosomes and their excretion into the urine due to defec-
tive degradation of these products. Urine analysis can be
helpful for diagnosis, although cases without urine ab-
normalities have been reported in the literature, and
detection of the sialylated products can be expensive and
labor intensive.6,7 The observed different disease severities
have resulted in division into the milder type I phenotype,
also referred to as “cherry red spotmyoclonus syn-
drome” in which clinical signs usually only become
obvious in adulthood, and themore severe type II,which is
congenital or has infantile onset. Individuals affected by
sialidosis type II exhibit typical storage disease features,
such as coarse face and hepatomegaly. Developmental
delay is also usually observed.8 Nephrosialidosis was
already recognized as a part of the phenotypic spectrum of
sialidosis II in 1978; however, only 16 cases have been
described in the literature to date.9–25
Here, we describe the implementation of parental
WES to deﬁne the underlying molecular cause of
nephrotic syndrome in a deceased child. Unexpectedly,
this led to a sialidosis type II diagnosis.Kidney International Reports (2018) 3, 1454–1463Nephrosialidosis is an ultra-rare disorder; therefore, it
lacks comprehensive information about the clinical
course. We provide a summary about all of the cases
published to date. Our results serve as an example for
using parental WES for molecular diagnosis of genetic
renal disorders when patient DNA is not suitable for
WES.
METHODS
Human DNA
Parental consent was given for genetic studies as part
of the clinical diagnostic workup with approval from
the local ethics committee. Genomic DNA was extrac-
ted from ethylenediamine tetraacetic acid blood using a
standard commercial kit (Qiagen, Germantown, MD).
DNA amounts were quantiﬁed using Bioanalyzer
(Agilent, Santa Clara, CA), and DNA integrity was
conﬁrmed by running 500 ng of DNA on an
ethidiumbromide-containing 1% agarose gel.
Whole-Exome Sequencing
WES was performed as previously described.26,27 In
brief, 5 mg of DNA from both parents were sent to
Novogene Ltd (Hong Kong, China), where WES was
performed using the Agilent Sure Select Human whole
exome kit V.6 (Agilent Technologies, Santa Clara, CA)
for enrichment. Sequencing was undertaken on a PE
150 HiSeq machine (Illumina, San Diego, CA). Read
alignment and variant calling were performed with
GATK (genome analysis toolkit) using default parame-
ters with the human genome assembly hg19 (GRCh37)
as reference. The obtained raw sequencing data were in
the range of 12 to 13 GB; the raw depth achieved was
257 to 266, average depth on target was 126 to
144, coverage of targeted regions was >99%, tar-
geted regions covered with a depth of at least 4 were
>99%, targeted regions covered with a depth of at
least 10 were 98.6% to 99.1%, targeted regions
covered with a depth of at least 20 were 96.5% to
97.2%, and targeted regions covered with a depth of at
least 50 were 93.1% to 94.8%. Splice sites were
deﬁned within 10 bp next to intron-exon/exon-intron
boundaries.
Variant Filtering
A stepwise ﬁltering procedure was implemented,
starting with ﬁltering out any variants with a minor
allele frequency $1% in control databases (Exome
Aggregation Consortium, Genome Aggregation Data-
base, dbSNP, the 1000 Genomes Project human poly-
morphism database and National Heart, Lung and
Blood Institute Exome Sequencing Project; see
Supplementary Web Resources). In the second step,
only protein-coding non-synonymous, stop gain,1455
Figure 1. Variant ﬁltering strategy. Visualization of the speciﬁc stepwise approach implemented to identify rare deleterious variants carried by
both parents in a heterozygous state. MAF, minor allele frequency; WES, whole-exome sequencing.
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site variants were retained. Remaining variants were
then ﬁltered for variants that occurred in both parents
in a heterozygous state. Variants in genes known to
cause a human phenotype when mutated, as well as
novel variants (no reported frequency in any of the
public databases), were subsequently prioritized. See
Figure 1 for details.
Phenotypic Features Used for Variant Priorization
Initial phentoypic ﬁltering was performed for variants
in genes previously associated with any human
phenotype. Secondary variant priorization was per-
formed for variants in genes associated with a pheno-
type that was either congenital in nature or that
occurred during childhood and involved the kidneys,
including impaired renal function as determined by
blood creatinine measurements, proteinuria, hematuria,
abnormal renal ultrasound results (includingTable 1. Final variant ﬁltering for heterozygous variants shared between
Gene Variant
ASCL5 NM_001270601: c.503G>A:p.R168H
EBF1 NM_182708: c.1499C>A:p.P500H
ENOX1 NM_001127615: c.447A>T:p.L149F
CENPJ NM_018451: c. 1960G>A:p.A654T Seckel sy
CLCN2 NM_001171088: c. 1930C>T:p.R644W Le
FAH NM_000137: c. 692T>C:p.M231T
HPR NM_020995: c. 518T>C:p.V173A
KANK1 NM_153186:c. 1588A>T:p.T530S Spa
MFSD6L NM_152599:c. 687G>C:p.K229N
MYHA4 NM_017533: c. 2385A>G:p.I795M
NEU1 NM_000434: c.1109A>G; p.Tyr370Cys
ORA4K1 NM_001004063: c. 185T>C:p.L62S
PADI4 NM_012387:c.A926G:p.Y309C Sus
PRG4 NM_001127710: c.C1756T:p.P586S Ca
SOX10 NM_006941: c. 820G>A:p.G274S PCWH
TACR3 NM_001059: c. 824G>A:p.W275X H
ZNF141 NM_003441: c. 207G>C:p.K69N and
NM_003441: c. 212T>C:p.V71A
P
PCWH, peripheral demyelinating neuropathy, central dysmyelination, Waardenburg syndrome,
1456hyperechogenic kidneys, renal cysts, and smaller or
larger than normal kidneys), and abnormal renal bi-
opsy results in pathology (including a diagnosis of
ﬁbrosis, glomerulosclerosis, tubular casts, tubular at-
rophy, hypercellularity, and reported renal or urinary
tract malformations).
Sanger Sequencing
Polymerase chain reactions (PCR) reactions were per-
formed using 50 mg of genomic DNA using a standard
touchdown PCR protocol with 35 cycles. PCR protocol
and primer sequences are available upon request.RESULTS
Clinical Description
A 9-month Iranian female infant born as the ﬁrst
offspring of ﬁrst-cousin parents presented to the local
pediatric services with onset of edema in the lowerboth parents
Gene previously implicated
in human disease
Variant not previously identiﬁed
in population databases
þ
þ
þ
ndrome type 4, primary microcephaly
ucencephalopathy with ataxia
Tyrosinemia type 1
þ
stic quadriplegic cerebral palsy
þ
þ
Sialidosis þ
þ
ceptibility to rheumatoid arthritis
mptodactyly-arthropathy-coxa
vara-pericarditis syndrome
syndrome, Waardenburg syndrome
ypogonatropic hypogonadism
olydactyly, postaxial, type A6
and Hirschsprung disease.
Kidney International Reports (2018) 3, 1454–1463
Figure 2. Family pedigree and NEU1 mutation segregation confirmation by Sanger sequencing. As suggested by whole-exome sequencing, both
parents carry c.1109A/G in a heterozygous state, whereas the affected child was homozygous for the mutation. During our study, a healthy
sibling was born; however, no DNA was available for testing.
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admission, and organomegaly was noted. Urine analysis
revealed nephrotic range proteinuria. Facial dys-
morphism was present in the form of relatively course
facial features and low-set ears. The extended clinical
history revealed bilateral hearing loss, as well as a
history of seizures and developmental delay (e.g.,
delayed sitting). Skeletal radiographic survey revealed
no signs of skeletal dysplasia, but did reveal bilateral
hip dysplasia and brachycephaly. Chest x-ray showed
her heart was mildly enlarged and the presence of right
upper lobe pneumonia. Brain magnetic resonance im-
aging without contrast showed bilateral mild fronto-
temporal atrophy. An ophthalmology consultation did
not take place.
Due to clinically evident nephrotic syndrome, ste-
roid treatment was started, and a renal biopsy was
performed; however, only 4 glomeruli were identiﬁed
in the sample. Glomerular epithelial cells were
enlarged, containing large amounts of foamy or gran-
ular cytoplasm. Pronounced thickening of the base-
ment membrane was noted, but no signs of ﬁbrosis or
vasculitis were found. Tubule cells appeared polyg-
onal, enlarged and likewise showed granular to foamy
cytoplasm. Protein debris was observed inside theKidney International Reports (2018) 3, 1454–1463tubules. Subsequently, peritoneal dialysis was started;
however, as her clinical state declined, she was trans-
ferred to the pediatric intensive care unit where she
passed away after 5 days due to cardiovascular failure
with severe blood pressure ﬂuctuations.
Genetic Workup Using Parental WES
To establish a molecular diagnosis, in light of further
planning for the family, we decided to perform WES in
the parents due to insufﬁcient DNA amounts available
from the patient. More than 300,000 variants were re-
ported for each parent in either the homozygous or
heterozygous state. Subsequent variant ﬁltering was
performed for each parental data set as shown in
Figure 1, based on a variant frequency of <1% in
available databases, including the Exome Aggregation
Consortium, Genome Aggregation Database, dbSNP,
the 1000 Genomes Project human polymorphism data-
base, and National Heart, Lung and Blood Institute–
Exome Sequencing Project (see Supplementary Web
Resources), as well as protein coding changes and
splice site regions. We then proceeded to ﬁltering for
variants that occurred in both parents in the hetero-
zygous state, assuming the child was homozygous for
the disease-causing variant because of the1457
Table 2. Summary of previously reported nephrosialidosis cases
Patient This report 1 2 3 4 5 6 7
Author NA Maroteaux/Le Sec
et al.9,10
Maroteaux
et al.9
Aylsworth et al.11 Matsuda et al.13 Shimada/Okada et al.14,a Beck et al.15,b Yamano et al.16,a
Yr of Publication NA 1978 1978 1980 1983 1983/1984 1984 1986
Gender Female Male Female, sister P1 Male Male Female Female Male
Origin Iran Francec Francec Caucasian Japan Japan Germany Japan
Clinical presentation
Onset of symptoms 9 mo 4 mo,
psychomotor
retardation
First week,
hepatomegalie
Birth, bilateral
hydroceles
1 yr 5 mo, facial
dysmorphic signs,
abdominal distension
3 mo, psychomotor
retardation, coarse face,
dysostosis multiplex
Prenatal, hydrops
fetalis
3 days before birth,
ascites
Onset of proteinuria 9 mo 2 yr 19 mo 20 mo 19 mo No proteinuria birth (mild) Hypoproteinemia,
no proteinuria
Treatment w. Steroids Yes with no
effect
No No Yes without success NR No No No
Hepatosplenomegaly Yes Yes Yes Yes Yes Yes Yes NR
Skeleton
Facial dysmorphic
signs
Yes Yes Yes Yes Yes Yes Yes Yes
Dysostosis
multiplex/
osteoporosis
NR Yes Yes Yes Yes Yes NR NR
Nervous system
Psychomotor
retardation
Yes Yes Yes Yes Yes Yes NR NR
Other Mild fronto-
temporal
atrophy,
seizures
Muscular hypotonia Growth failure
Eyes
Corneal clouding/
cataracts
NR Yes Yes No No Yes NR Yes
Macular cherry-red
spot
NR NR NR No Yes No NR Yes
Other
Hernia No Yes NR Yes Yes NR NR NR
Ascites/edema Yes Yes NR Yes NR NR Yes Yes
Other Bilateral hip
dysplasia,
bialteral
hearing loss
Frequent upper
respiratory tract
infections
Frequent upper respiratory
tract infections
Petechia
Course Died aged 9 mo Died at the age
of 4.5 yr
NR NR NR Died of unknown
cause at 7 mo
Died at the age
of 6 mo
Died of respiratory
failure at 56
days
Diagnostics
Deﬁciency of a
neuraminidase in
lymphocytes/
ﬁbroblasts
Not tested Yes Yes Yes and mild
depression
of beta-
galactosidase
Yes Yes and depression of
beta-
galactosidase
Yes Yes
Vacuolated
lymphocytes
Not tested Yes Yes NR Yes NR NR Yes
Renal pathology:
FSGS/vacuolated
cells
Yes Yes NR NR Yes Yes Yes Yes
Genetic diagnosis Yes: NEU1
c.1105A>G
No No No No No No No
BMT, bone marrow transplant; FSGS, focal segmental glomerulosclerosis; HD, hemodialysis; NA, not applicable; NR, not reported; PD, peritoneal dialysis.
aPatients did not show proteinuria but abnormalities in the biopsy/autopsy of the kidney similar to those found in other nephrosialidose.
bA short summary of the table is displayed in Supplementary Table S1.
cPatient origin unknown, country where the treating hospital is located.
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Patient 8 9 10 11 12 13 14 15 16
Author Kelly/Roth
et al.17–19
Kashtan
et al.20
Toyooka
et al.16
Kanaka
et al.21
Tylki-Szymanska
et al.12
Ovali et al.22
b
Schiff et al.23 Caciotti
et al.24
Chen et al.25
Yr of Publication 1977,1981/1988 1981/1989 1993 1993 1996 1998 2005 2009 2011
Gender Female NR Male Male Male Female Female Female Male
Origin USA USAc Japan Switzerland Poland Turkeyc Francec NR China
Clinical presentation
Onset of symptoms Birth, facial
dysmorphic signs
6 mo,
macrocephaly
1 yr 7 mo NR Birth, hydrops
fetalis
Prenatal,
hydrops
fetalis
1.5 mo failure to
thrive,
vomiting
NR 12 mo,
edema of
scrotum
Onset of proteinuria 8 yr 2 yr 19 mo 6.5 yr 3.5 yr Birth (mild) 25 mo NR 2 yr
Treatment w. Steroids No Yes without
success
No No Yes without
success
No No NR Yes without
success
Hepatosplenomegaly Yes Yes Yes Yes Yes Yes Yes Yes NR
Skeleton
Facial dysmorphic
signs
Yes Yes Yes Yes Yes Yes Yes Yes NR
Dysostosis
multiplex/
osteoporosis
NR NR Yes NR NR NR Yes Yes NR
Nervous system
Psychomotor
retardation
Yes NR Yes NR Yes NR Yes Yes NR
Other Growth
retardation
Growth retardation Hyrocephalus Growth failure
Eyes
Corneal clouding/
cataracts
Yes Yes NR Yes Yes No NR NR NR
Macular cherry-red
spot
No NR Yes Yes Yes No NR NR No
Other Optic nerve
degeneration
Hernia NR Yes NR NR Yes Yes NR NR NR
Ascites/edema Yes NR NR NR Yes Yes Yes Yes Yes
Other Joint restriction,
gingival
hypertrophy,
cardiomegaly
Chronic otitis
media
Severe recurrent
epistaxis with
massive loss of
blood
Gingival
hyperplasia
Petechia,
teleangi-
ectases
Course PD followed
by HD at 9 yr,
died from sepsis
at 9 yr 8 mo
Died at the
age of 9 yr
Died of multiple
organ failure
at 8 yr
Died of cardiac
failure at 8.5 yr
Died at the
age of 4 yr
Died at 27
days
BMT (9 mo), HD
(6 yr), at 11
yr of age poor
general
condition
Died at the
age of 1 yr
Died at
the age of
2.5 yr
Diagnostics
Deﬁciency of a
neuraminidase in
lymphocytes/
ﬁbroblasts
Yes Yes Yes Yes Yes and
depression of
beta-
galactosidase
No but
elevated
levels of
sialic acid
in urine
Yes Yes Yes
Vacuolated
lymphocytes
NR NR NR Yes NR Yes NR NR NR
Renal pathology:
FSGS/vacuolated
cells
Yes Yes Yes NR NR NR Yes NR Yes
Genetic diagnosis No No No No No No No Yes: NEU1
c.807 þ
1G>A
No
Table 2. (Continued)
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shared heterozygous variants. We prioritized variants
in genes known to cause a human phenotype when
mutated (technically, a Mendeliome analysis), as well as
other variants, which we deﬁned as novel because
there was no reported frequency in the public data-
bases (e.g., Exome Aggregation Consortium or the
Genome Aggregation Database) or variants that
occurred in genes previously linked to human disease.
Among these variants, we prioritized variants that
fulﬁlled both criteria. Ten genes contained variants
shared between both parents, which were previously
implicated in human disease (CENPJ, CLCN2, FAH,
KANK1, NEU1, PADI4, PRG4, SOX10, TACR3,
ZNF141). Variants in 8 genes (ASCL5, EBF1, ENOX1,
HPR, MFSD6L, MYHA4, NEU1, ORA4K1) were not
present in population databases (Table 1). Combining
both ﬁltering steps resulted in only 1 variant: NEU1
NM_000434: c. 1109A>G, p.Y370C (see Supplementary
Figure S1 for the variant location in the binary align-
ment map [BAM] ﬁles). Fifty NEU1 mutations identiﬁed
as causative for sialidosis I/II (OMIM 256550) were re-
ported to date in the Human Gene Mutation database
(www. http://www.hgmd.cf.ac.uk/ac/index.php),
among which was the variant we identiﬁed, as origi-
nally reported by Bonten et al. in 2000.5 Furthermore,
the phenotype in our case, with coarse facial features,
organomegaly, neurological problems, and foamy cyto-
plasm found in the renal biopsy material, matched the
phenotypic criteria of nephrosialidosis, which was re-
ported in <20 cases in the literature. Subsequent Sanger
sequencing conﬁrmed the affected individual carried
the NEU1 missense variant in a homozygous state (see
Figure 2 for pedigree and sequencing results). The
affected nucleotide was highly conserved (phyloP 4. 56),
and so was the amino acid among species, including that
in Mus musculus (mouse), Danio rerio (zebraﬁsh), and
Xenopus tropicalis (frog). Tyrosine and cysteine are
physiochemically distant, and the variant was predicted
as disease-causing (score 1.0) by mutation taster
prediction software (www.mutationtaster.org; see
Supplementary Web Resources). According to the
guidelines, the identiﬁed variant shows strong evidence
for pathogenicity (PS1 variant) and was classiﬁed as
pathogenic according to the American College of Med-
ical Genetics and Genomics (ACMG) variant classiﬁca-
tion rules. NEU1 function and the most severely
affected organs in sialidosis are outlined in Figure 3.
Clinical and Molecular Features of Previously
Reported Nephrosialidosis Cases
Nephrosialidosis represents an ultra-rare disorder and
therefore clinical descriptions are sparse. We screened
PubMed for previous reports and found 16 cases,1460which are summarized in detail in Table 2 and a short
summarizing description in Supplementary Table S1.
Only 1 of these cases had been molecularly conﬁrmed.
The main onset of proteinuria was at age 2 to 3 years,
with few earlier or later cases. Four of 16 patients
received steroid treatment with no improvement. Renal
pathology revealed mainly FSGS with vacuolated cells.
Extrarenal manifestations were found in all reported
patients, with most presenting with hepatomegaly,
whereas corneal clouding and a cherry-red spot on the
macula was only observed in approximately 50% of
cases. Most patients showed extrarenal symptoms
before the onset of renal manifestations. The disease
course was unfavorable in most cases, with 14 of 16
cases no longer alive at the time of reporting. It is
unknown if the remaining 2 cases survived or died at a
later stage.CONCLUSIONS
Sialidosis is a rare autosomal, recessively inherited
disorder that results in lysosomal accumulation of sia-
lyated protein products and excretion of such products
in the urine. Diagnosis is usually made based on clinical
criteria, including classical storage disorder symptoms,
such as facial dysmorphism and organomegaly. Cherry
red spots at ophthalmological examination and neuro-
logical symptoms in combination with biochemistry
analyses for sialyated products in the urine and/or in
tissue samples (e.g., ﬁbroblasts) can also be used for
diagnosis. However, such analyses may not be available
in countries with low socioeconomic status. In our case,
the patient came to the attention of medical services
due to nephrotic syndrome, and as a result of rapid
deterioration of her health with a fatal outcome, a
diagnosis could not be made before her death. How-
ever, the family was desperate to understand what
caused her death and to ascertain knowledge for
further family planning. We suspected a storage dis-
ease because of the phenotype of the infant, which
included coarse facial features, organomegaly, neuro-
logical problems, and foamy cytoplasm found in the
renal biopsy material. However, because of the family’s
consanguinity, and therefore, a possibility of 2 reces-
sive disorders segregating (storage disorder and
nephrotic syndrome) within the family, we decided to
perform WES instead of targeted gene analyses. The
number of possibly causative genes was extensive, and
WES was the most economic test ($450 USD per sample,
including bioinformatics) with the best chances to
identify the underlying genetic cause. Due to the un-
availability of sufﬁcient high-quality DNA for the in-
dex case, we sequenced both parents instead, because
we previously successfully identiﬁed a causativeKidney International Reports (2018) 3, 1454–1463
Figure 3. Schematic of NEU1 function and organ involvement in
sialidosis. NEU1 (a-neuraminidase) functions together with
cathepsin as sialidase, removing sialic acid from glycoproteins and/
or peptides and oligosaccharides. Accumulation of sialylated
products in lysosomes causes progressive organ dysfunction,
including the kidneys, liver, heart, brain, eyes, and bones.
R Marooﬁan et al.: Parental WES Diagnoses Sialidosis as Cause of NS TRANSLATIONAL RESEARCHrecessive gene using parental samples and checked
those samples for a shared heterozygous disease-
causing variant.28 This allowed us to save the pa-
tient’s small amounts of DNA for Sanger sequencing.
Although our method is more effective in consanguine
families because ﬁltering for a shared variant is
possible, it is also feasible for nonrelated parents by
ﬁltering for heterozygous variants in the same genes.
We applied a ﬁltering cascade that technically con-
tained a Mendeliome analysis. Mendeliome NGS
sequencing represents a targeted WES approach in
which only genes known to cause human disease are
included instead of the genome-wide approach in WES.
Numerous medico-biological companies offer this
sequencing approach, and some genetics centers apply
this method for variant detection rather than WES as
the ﬁrst-line method. With regard to cost, it is usually
not signiﬁcantly cheaper, despite the fact that less
sequence reads are required, because sample prepara-
tion process and time are equal to WES but less DNA
input is required (w200 ng compared with several
micrograms for WES). This is still more than that used
for a single PCR with subsequent Sanger sequencing, in
which 25 to 50 ng are sufﬁcient. Therefore, in our case,
we opted not to attempt targeted WES but instead used
parental samples for WES. However, it can be an
interesting approach for cases in which only 500 ng or
1 mg of DNA is available. Although an advantage ofKidney International Reports (2018) 3, 1454–1463targeted WES is less bioinformatic data usage, which
allows easier and faster data analysis, the disadvantage
is that due to rapid discovery of novel human disease-
causing genes, targeted exome kits are never “up to
date”; therefore, recently published data on genes are
not covered. Furthermore, by default, targeted WES
does not offer the possibility of novel gene identiﬁca-
tion. In contrast, targeted WES may offer slightly
better coverage of known disease-causing genes due to
optimizations and less genes to be covered by the
sequencing method; however, we achieved a depth of
4 for 99%, 10 for 98.6% to 99.1%, 20 for 96.5%
to 97.2%, and 50 for 93.1% to 94.8% of targeted
regions, with 99% of targeted regions covered, which
is usually sufﬁcient.
The histological changes reported for the renal bi-
opsy in our case are not unique to storage disorders.
Some vacuolization of visceral epithelial cells also oc-
curs with other forms of nephrotic syndrome, such as
FSGS, and minimal change disease, but not to the same
extent, and usually with empty vacuoles.25 In contrast
to some previously reported nephrosialidosis cases, no
sclerosis was found in our biopsy, and the glomerular
basement membrane likewise appeared normal. As
pointed out by Chen et al.,25 Denys-Drash Syndrome
(OMIM 194080) can also present with dysmorphic
facial features, neurodevelopmental delay, and
nephrotic syndrome, although usually congenitally and
foamy podocytes have also likewise been described in
Alport syndrome (OMIM 301050). In addition, action
myoclonus renal failure syndrome caused by SCARB2
mutations presents with overlapping features
compared with nephrosialidosis (e.g., progressive
neurological diseases, FSGS, nephrotic syndrome, and
renal failure). Histology can show vacuolar cytoplasm
and granular deposits within the renal tubules.29
Therefore, these conditions should be considered in
the differential diagnosis and rendering of WES, rather
than considering hypothesis-driven, single-gene
sequencing to be more efﬁcient.
Hepatomegaly seems to be the most common extra-
renal feature in nephrosialidosis patients, whereas
pathognomonic signs (e.g., a cherry red macular spot or
corneal clouding) occur only in approximately 50% of
cases. In most previously reported cases, extrarenal
symptoms occurred well before renal manifestations;
however, in areas of the world with difﬁcult to access
medical care or with limited diagnostic possibilities
(e.g., our case), nephrotic range proteinuria can be the
ﬁrst symptom that brings a patient to medical atten-
tion. As for the previously reported 16 nephrosialidosis
cases, only 1 was conﬁrmed on a molecular level; pu-
tative genotype-phenotype correlations cannot be1461
TRANSLATIONAL RESEARCH R Marooﬁan et al.: Parental WES Diagnoses Sialidosis as Cause of NSmade. It remains unclear why some patients develop
renal disease, whereas others do not.
In summary, our ﬁndings underline the power of
WES for molecular diagnosis in rare diseases. Our
ﬁndings indicate that primary WES analysis is a reli-
able diagnostic measure for a relatively cheap price,
especially in areas of the world where elaborate
biochemical analyses are not available. Parental
sequencing should be attempted if there is not enough
DNA or only low-quality DNA is available from the
index case. Furthermore, nephrosialidosis should be
considered as a differential diagnosis in patients with
steroid resistant nephrotic syndrome with dysmorphic
facial features and developmental delay.DISCLOSURE
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SUPPLEMENTARY MATERIAL
Table S1. Short summarizing description of previously
reported nephrosialidosis cases
Figure S1. Integrative genomics viewer (IGV) screenshot
visualizing the heterozygous NEU1 mutation detected in
whole-exome sequencing (WES) data of both parents.
Web Resources.
Supplementary material is linked to the online version of
the paper at www.kireports.org.
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